Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Autolomous Ltd.. (5/4/21). "Press Release: Autolomous Receives Loan from UK Research and Innovation to Expedite the Digitization of Batch Verification in Cell and Gene Therapy manufacturing". London.

Region Region United Kingdom (GB)
Organisations Organisation Autolomous Ltd.
  Organisation 2 UK Research and Innovation (UKRI)
  Group United Kingdom (GB) (govt)
Product Product  business development (state/region)
Index term Index term Autolomous–United Kingdom (govt): credit, 202104– UKRI loan for further development of AutoloMATE platform
Person Person Hunter, Neil (Image Box 201310– Life Science Director before Andrew Loyd Associates)

Autolomous LTD, the market leading developer of critical manufacturing management systems for cell and gene therapies, today announces it has received a loan from UK Research and Innovation (UKRI), the public innovation agency, as part of the medicine’s manufacturing challenge.

The loan is provided as additional support for Autolomous to expedite development of AutoloMATE-Assist, its digital batch verification technology for cell and gene therapies (CGT). The project has commenced in April 2021 and is expected to last 24 months.

AutoloMATE-Assist is the third module from Autolomous’ digital platform AutoloMATE™. This is a business critical robust digital platform for efficiency, scalability and process streamlining of the GMP manufacturing and batch verification of cell & gene therapies. The other AutoloMATE modules are AutoloMATE-eBMR, which digitizes batch manufacturing records, and AutoloMATE-CLOCK that provides complete scheduling of all critical manufacturing variables. The three modules of the AutoloMATE platform will enable manufacturers of advanced therapies and cell and gene therapies to develop an end to end manufacturing strategy.

AutoloMATE-Assist will be the first digital batch verification solution available to the market which will be fully integrated with both an electronic batch manufacturing record solution (eBMR), AutoloMATE-eBMR, and scheduling capability, AutoloMATE-CLOCK. The completion of a digital batch verification solution will be critical for the scale up of cell and gene and advanced therapies. Currently, paper based batch verification is providing one of the most significant bottlenecks in the cell and gene therapy manufacturing sector. This will increase in intensity as the industry continues to scale. The alleviation of this bottleneck will be absolutely critical as more advanced therapies progress through clinical stages into commercialization.

“This support from UKRI demonstrates the critical consideration given to batch verification as part of the ever-expanding CGT infrastructure. The selection of Autolomous for the award also provides confidence by UKRI in our ability to develop digital batch verification technology, and its implementation within our wider portfolio of critical manufacturing management systems for CGT,” said Alexander Seyf, CEO, Autolomous. “This loan will enable Autolomous to expedite our development of a critical part of our end to end solution for cell and gene therapy manufacturers. It will provide this sector with critically-needed automation in the supply chain, supporting a safe and controlled delivery of more therapies to more patients.”

About Autolomous

Autolomous LTD is the market leading developer of critical manufacturing management systems for cell and gene therapies. Autolomous internationally deploys fully integrated, digitized and automated supply chain software solutions. These solutions utilize emerging technologies such as Distributed Ledger technology and Internet of Things (IoT) to ensure compliance with current and future regulatory requirements. As a result, Autolomous enables manufacturers to reduce costs and deliver cell & gene therapies to more patients.

Autolomous’ platform, AutoloMATE™ is a business critical robust digital solution increasing efficiency, scalability and process streamlining of the GMP manufacturing and product release of cell & gene therapies.

Autolomous LTD is headquartered in London. The company was founded in 2019 by four professionals with combined experience covering fifty years in advanced therapies and medical practice and thirty five years in technology, software and business.

About UKRI

Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. Innovate connects businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. Innovate fund business and research collaborations to accelerate innovation and drive business investment into R&D. Innovate’s support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit

Contact Information:

Image Box Communications
Neil Hunter / Michelle Boxall
Tel +44 (0)20 8943 4685 /

Record changed: 2021-10-13


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Autolomous Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Plain Stupid Simple 650x80px

» top